After participating in this educational activity, attendees should be able to:
1. Describe poly-ADP-ribose polymerase (PARP) inhibitors mechanism of action.
2. Evaluate PARP inhibitor role in treatment for BRCA1/2+ metastatic breast cancer.
3. Review a patient case of metastatic breast cancer.
4. Apply available literature to clinical practice.
Catie Chatowsky, PharmD
PGY1 Pharmacy Resident
Baystate Medical Center
None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.
- 1.00 ACPE Contact Hours